3.61 USD
▲+0.02+3.14%
盘后 3.51 +0.29%
2026-08-03
市值
$399.15M
市盈率
—
EPS
-1.07
股息率
—
52 周区间
1.69 – 5.17
成交量
2.52M
Beta
2.94
目标价
13.33
52W 低 1.6952W 高 5.17
价格走势
公司简介
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat...